Quantitative systems pharmacology and the personalized drug-microbiota-diet axis

Current Opinion in Systems Biology

Volumn 4, Issue , 2017, Pages 43-52

  Thiele, Ines ^a   Clancy, Catherine M ^a   Heinken, Almut ^a   Fleming, Ronan M T ^a  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

Author keywords

Constraint based modeling; Drug metabolism; Gut microbiota; Pharmacokinetic modeling; Precision medicine

Indexed keywords

COMPUTATIONAL MODEL; COMPUTER MODEL; DIET; DRUG INTERACTION; DRUG METABOLISM; DRUG RESPONSE; HUMAN; HYBRID; INTESTINE FLORA; MICROBIAL METABOLISM; NONBIOLOGICAL MODEL; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOKINETICS; PHARMACOLOGY; QUANTITATIVE STUDY; REVIEW;

EID: 85045297392     PISSN: None     EISSN: 24523100     Source Type: Journal    
DOI: 10.1016/j.coisb.2017.06.001     Document Type: Review

References (72)

1. Nebert D.W., Zhang G., Vesell E.S. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008, 40:187-224.
2. Haiser H.J., Turnbaugh P.J. Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res: Off J Ital Pharmacol Soc 2013, 69:21-31.
3. Mardinoglu A., Shoaie S., Bergentall M., Ghaffari P., Zhang C., Larsson E., Backhed F., Nielsen J. The gut microbiota modulates host amino acid and glutathione metabolism in mice. Mol Syst Biol 2015, 11:834.
4. Jamei M. Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance. Curr Pharmacol Rep 2016, 2:161-169.
5. Kitano H. The grand challenge of systems biomedicine 2013, World Health Summit Yearbook.
6. Wilson I.D. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc Natl Acad Sci U. S. A 2009, 106:14187-14188.
7. Schork N.J. Personalized medicine: time for one-person trials. Nature 2015, 520:609-611.
8. Campbell J.E., Gossell-Williams M., Lee M.G. A review of pharmacovigilance. West Indian Med J 2014, 63:771-774.
9. Alomar M.J. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J 2014, 22:83-94.
10. Clayton T.A., Baker D., Lindon J.C., Everett J.R., Nicholson J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U. S. A 2009, 106:14728-14733.
11. Drew L. Pharmacogenetics: the right drug for you. Nature 2016, 537:S60-S62.
12. Nayak R.R., Turnbaugh P.J. Mirror, mirror on the wall: which microbiomes will help heal them all?. BMC Med 2016, 14:72.
13. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., Nielsen T., Pons N., Levenez F., Yamada T., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
14. Falony G., Joossens M., Vieira-Silva S., Wang J., Darzi Y., Faust K., Kurilshikov A., Bonder M.J., Valles-Colomer M., Vandeputte D., et al. Population-level analysis of gut microbiome variation. Science 2016, 352:560-564. New York, N. Y.
15. Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., Pettersson S. Host-gut microbiota metabolic interactions. Science 2012, 336:1262-1267. New York, N. Y.
16. Maurice C.F., Haiser H.J., Turnbaugh P.J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013, 152:39-50.
17. Klaassen C.D., Cui J.Y. Review: mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids. Drug Metab Dispos 2015, 43:1505-1521.
18. Tralau T., Sowada J., Luch A. Insights on the human microbiome and its xenobiotic metabolism: what is known about its effects on human physiology?. Expert Opin Drug Metab Toxicol 2015, 11:411-425.
19. Haiser H.J., Turnbaugh P.J. Is it time for a metagenomic basis of therapeutics?. Science 2012, 336:1253-1255. New York, N. Y.
20. Spanogiannopoulos P., Bess E.N., Carmody R.N., Turnbaugh P.J. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev 2016, 14:273-287.
21. Haiser H.J., Gootenberg D.B., Chatman K., Sirasani G., Balskus E.P., Turnbaugh P.J. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 2013, 341:295-298. New York, N. Y.
22. Haiser H.J., Seim K.L., Balskus E.P., Turnbaugh P.J. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes 2014, 5:233-238.
23. Moya A., Ferrer M. Functional redundancy-induced stability of gut microbiota subjected to disturbance. Trends Microbiol 2016, 24:402-413.
24. Rowland M. Physiologically-based pharmacokinetic (PBPK) modeling and simulations principles, methods, and applications in the pharmaceutical industry. CPT Pharmacomet Syst Pharmacol 2013, 2:e55.
25. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003, 42:883-908.
26. Knight-Schrijver V.R., Chelliah V., Cucurull-Sanchez L., Le Novere N. The promises of quantitative systems pharmacology modelling for drug development. Comput Struct Biotechnol J 2017, 14:363-370.
27. Kell D.B., Goodacre R. Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discov today 2014, 19:171-182.
28. Upton R.N., Foster D.J., Abuhewla A.Y. An introduction to physiologically-based pharmacokinetic models. Paediatr Anaesth 2016, 26:1036-1046.
29. Nestorov I. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2007, 3:235-249.
30. Jones H., Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacomet Syst Pharmacol 2013, 2:e63.
31. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 2012, 92:50-61.
32. Sager J.E., Yu J., Ragueneau-Majlessi I., Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos 2015, 43:1823-1837.
33. Yoshida K., Maeda K., Kusuhara H., Konagaya A. Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models. BMC Syst Biol 2013, 7(Suppl 3):S3.
34. Guebila M.B., Thiele I. Model-based dietary optimization for late-stage, levodopa-treated, Parkinson's disease patients. Npj Syst Biol Appl 2016, 2:16013.
35. Agoram B., Woltosz W.S., Bolger M.B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001, 50(Suppl 1):S41-S67.
36. Yu L.X., Amidon G.L. Characterization of small intestinal transit time distribution in humans. Int J Pharm 1998, 171:157-163.
37. Price P.S., Conolly R.B., Chaisson C.F., Gross E.A., Young J.S., Mathis E.T., Tedder D.R. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003, 33:469-503.
38. McNally K., Cotton R., Hogg A., Loizou G. PopGen: a virtual human population generator. Toxicology 2014, 315:70-85.
39. Strolin Benedetti M., Whomsley R., Baltes E.L. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005, 1:447-471.
40. Barrett J.S., Della Casa Alberighi O., Laer S., Meibohm B. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 2012, 92:40-49.
41. Abduljalil K., Furness P., Johnson T.N., Rostami-Hodjegan A., Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2012, 51:365-396.
42. Young J.F., Branham W.S., Sheehan D.M., Baker M.E., Wosilait W.D., Luecke R.H. Physiological "constants" for PBPK models for pregnancy. J Toxicol Environ Health 1997, 52:385-401.
43. Thompson C.M., Johns D.O., Sonawane B., Barton H.A., Hattis D., Tardif R., Krishnan K. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J Toxicol Environ Health B Crit Rev 2009, 12:1-24.
44. Palsson B. Systems biology: properties of reconstructed networks 2006, Cambridge University Press, Cambridge.
45. Thiele I., Swainston N., Fleming R.M., Hoppe A., Sahoo S., Aurich M.K., Haraldsdottir H., Mo M.L., Rolfsson O., Stobbe M.D., et al. A community-driven global reconstruction of human metabolism. Nat Biotechnol 2013, 31:419-425.
46. Agren R., Mardinoglu A., Asplund A., Kampf C., Uhlen M., Nielsen J. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol Syst Biol 2014, 10:721.
47. Swainston N., Smallbone K., Hefzi H., Dobson P.D., Brewer J., Hanscho M., Zielinski D.C., Ang K.S., Gardiner N.J., Gutierrez J.M., et al. Recon 2.2: from reconstruction to model of human metabolism. Metab: Off J Metab Soc 2016, 12:109.
48. Sahoo S., Haraldsdottir H.S., Fleming R.M., Thiele I. Modeling the effects of commonly used drugs on human metabolism. FEBS J 2015, 282:297-317.
49. Jamshidi N., Palsson B.O. Systems biology of SNPs. Mol Syst Biol 2006, 2:38.
50. Sahoo S., Franzson L., Jonsson J.J., Thiele I. A compendium of inborn errors of metabolism mapped onto the human metabolic network. Mol Biosyst 2012, 8:2545-2558.
51. Pagliarini R., Castello R., Napolitano F., Borzone R., Annunziata P., Mandrile G., De Marchi M., Brunetti-Pierri N., di Bernardo D. In silico modeling of liver metabolism in a human disease reveals a key enzyme for histidine and histamine homeostasis. Cell Rep 2016, 15:2292-2300.
52. Shaked I., Oberhardt M.A., Atias N., Sharan R., Ruppin E. Metabolic network prediction of drug side effects. Cell Syst 2016, 2:209-213.
53. Chang R.L., Xie L., Bourne P.E., Palsson B.O. Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol 2010, 6.
54. Wadehn F.S.S., Eissing T., Krauss M., Kuepfer L. A multiscale, model-based analysis of the multi-tissue interplay underlying blood glucose regulation in diabetes. EMBC 2016, (Orlando).
55. Krauss M., Schaller S., Borchers S., Findeisen R., Lippert J., Kuepfer L. Integrating cellular metabolism into a multiscale whole-body model. PLoS Comput Biol 2012, 8:e1002750.
56. Toroghi M.K., Cluett W.R., Mahadevan R. A multi-scale model of the whole human body based on dynamic parsimonious flux balance analysis. IFAC-PapersOnLine 2016, 49:937-942.
57. Gille C., Bolling C., Hoppe A., Bulik S., Hoffmann S., Hubner K., Karlstadt A., Ganeshan R., Konig M., Rother K., et al. HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology. Mol Syst Biol 2010, 6:411.
58. Bordbar A., Feist A.M., Usaite-Black R., Woodcock J., Palsson B.O., Famili I. A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology. BMC Syst Biol 2011, 5:180.
59. Sahoo S., Thiele I. Predicting the impact of diet and enzymopathies on human small intestinal epithelial cells. Hum Mol Genet 2013, 22:2705-2722.
60. Uhlen M., Fagerberg L., Hallstrom B.M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson A., Kampf C., Sjostedt E., Asplund A., et al. Proteomics. Tissue-based map of the human proteome. Science 2015, 347:1260419. New York, N. Y.
61. Aurich M.K., Thiele I. Computational modeling of human metabolism and its application to systems biomedicine. Methods Mol Biol 2016, 1386:253-281. Clifton, N. J.
62. Magnusdottir S., Heinken A., Kutt L., Ravcheev D.A., Bauer E., Noronha A., Greenhalgh K., Jager C., Baginska J., Wilmes P., et al. Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota. Nat Biotechnol 2017, 35:81-89.
63. Heinken A., Thiele I. Systematic prediction of health-relevant human-microbial co-metabolism through a computational framework. Gut Microbes 2015, 6:120-130.
64. Klunemann M., Schmid M., Patil K.R. Computational tools for modeling xenometabolism of the human gut microbiota. Trends Biotechnol 2014, 32:157-165.
65. Ravcheev D.A., Thiele I. Genomic analysis of the human gut microbiome suggests novel enzymes involved in quinone biosynthesis. Front Microbiol 2016, 7.
66. Shoaie S., Ghaffari P., Kovatcheva-Datchary P., Mardinoglu A., Sen P., Pujos-Guillot E., de Wouters T., Juste C., Rizkalla S., Chilloux J., et al. Quantifying diet-induced metabolic changes of the human gut microbiome. Cell metab 2015, 22:320-331.
67. Nogiec C.D., Kasif S. To supplement or not to supplement: a metabolic network framework for human nutritional supplements. PLoS One 2013, 8:e68751.
68. Dontchev A.L., Rockafellar R.T. Primal-dual solution perturbations in convex optimization. Set-Valued Anal 2001, 9:49-65.
69. Fleming R.M., Maes C.M., Saunders M.A., Ye Y., Palsson B.O. A variational principle for computing nonequilibrium fluxes and potentials in genome-scale biochemical networks. J Theor Biol 2012, 292:71-77.
70. Mardsen J.E., West M. Discrete mechanics and variational integrators. Acta Numer 2001, 10:357-514.
71. Ma, D.Y.L.; Fleming, R.M.T.; Thiele, I.; Palsson, B.O.; Saunders, M.A. (2016). Reliable and efficient solution of genome-scale models of Metabolism and macromolecular Expression.
72. Campbell J.M., Stephenson M.D., Bateman E., Peters M.D., Keefe D.M., Bowen J.M. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogen J 2016, 17:21-28.